Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.
LAMIVUDINE AND ZIDOVUDINE — MACLEODS PHARMS LTD, approved 2019-12-13 (ANDA090679).
28,817 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.